Its role as a glucagon-like peptide-1 (GLP-1) agonist involves influencing appetite and insulin secretion
A responsible plan may include adequate protein intake, resistance training, walking or other appropriate activity, body composition tracking when available, lab monitoring, gradual dose escalation when appropriate, nutrition support during appetite reduction, hydration and electrolyte guidance, monitoring fatigue or excessive appetite suppression, and evaluation for hormone, thyroid, or nutrient issues when relevant
Clinically significant weight lossgenerally defined as 5% or more of baseline body weighttypically becomes apparent after reaching the maintenance dose, which may take 16-20 weeks depending on the specific medication and titration schedule
Semaglutide Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
Every article is written or reviewed by the YourEra clinical team, the same physicians, nurses, and nutritionists who care for members
Preclinical Testing: Before human trials can begin, a new drug undergoes laboratory testing and animal studies to assess its safety and biological activity
